IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Open accessThe DOI matches its Crossref record; 40 of the 50 references it cites were found in a registry or an index.
Abstract
The anti-tumor activity of recombinant mAb's directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets.However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo.We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12.This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes.Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcγRIII) and the IL-12 receptor expressed on NK cells.Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell-derived cytokines with the capacity to augment anti-tumor immunity.These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, increase in IL-12 levels might enhance the efficacy of immunotherapy by increasing the production of IFN-ɤ to stimulate the development and enhance the cytotoxicity of activated NK cells (100) and T cells and to accelerate the differentiation of CD4+ Th0 cells toward the Th1 phenotype, thus improving antibody-dependent cellular cytotoxicity (101).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [100]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses
Gately, M. K., Renzetti, L. M., Magram, J., Stern, A. S., Adorini, L., Gubler, U., & Presky, D. H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.495 · Cited by 1,231
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A. A., Doherty, P. C., Grosveld, G. C., et al. (1996) · Nature · doi:10.1038/382171a0 · Cited by 1,180
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Self-citationPegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Research works printed but not linked: 10
- Sarup, J.C., et al. 1991. Characterization of an anti-p185HER2 mono- clonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:72-82.
- Baselga, J., and Albanell, J. 2001. Mechanisms of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12:S35-S41. · doi:10.1023/a:1011163824080
- Sliwkowski, M.X., et al. 1999. Nonclinical studies addressing the mech- anism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60-70.
- Penichet, M.L., et al. 1999. In vivo properties of three human HER2/neu- expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49:179-188.
- Fleming, G.F., et al. 1999. A phase I CALGB trial of recombinant human anti-HER2 monoclonal antibody plus low-dose interleukin2 in solid tumors. Proc. Am. Soc. Clin. Oncol. 18:184a. (Abstr. 710)
- Weiner, L.M., et al. 1995. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:4586-4593.
- Penichet, M.L., Dela Cruz, J.S., Shin, S.U., and Morrison, S.L. 2001. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum. Antibodies. 10:43-49. · doi:10.3233/hab-2000-10107
- Peng, L.S., Penichet, M.L., and Morrison, S.L. 1999. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163:250-258. · doi:10.4049/jimmunol.163.1.250
- Cavallo, F., et al. 1999. Immune events associated with the cure of estab- lished tumors and spontaneous metastases by local and systemic inter- leukin-12. Cancer Res. 59:414-421.
- Parihar, R. et al. 2001. A phase I trial of Herceptin and interleukin-12 in patients with HER2-overexpressing malignancies. Proc. Am. Soc. Clin. Oncol. 20:258a. (Abstr. 1031)
Cited by
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Human natural killer cell development and biology
Farag, S. S., & Caligiuri, M. A. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 506
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
Srivastava, R. M., Lee, S. C., Andrade Filho, P. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López-Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 318
Trotta, R., Col, J. D., Yu, J., Ciarlariello, D., Thomas, B., Zhang, X., Allard, J., Wei, M., Mao, H., Byrd, J. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3784 · Cited by 275
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response
Li, T., Cheng, H., Yuan, H., Xu, Q., Shu, C., Zhang, Y., Xu, P., Tan, J., Rui, Y., Li, P., et al. (2016) · Scientific Reports · doi:10.1038/srep19049 · Cited by 253
Stiff, A., Trikha, P., Mundy-Bosse, B., McMichael, E., Mace, T. A., Benner, B., Kendra, K., Campbell, A., Gautam, S., Abood, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0691 · Cited by 244
Self-citationTargeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Sharkey, R. M., & Goldenberg, D. M. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.4.226 · Cited by 242
Gleason, M. K., Verneris, M. R., Todhunter, D. A., Zhang, B., McCullar, V., Zhou, S. X., Panoskaltsis-Mortari, A., Weiner, L. M., Vallera, D. A., & Miller, J. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0692 · Cited by 238
The Use of Lentinan for Treating Gastric Cancer
Ina, K., Kataoka, T., & Ando, T. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313050002 · Cited by 229
miR-155 regulates IFN-γ production in natural killer cells
Trotta, R., Chen, L., Ciarlariello, D., Josyula, S., Mao, C., Costinean, S., Yu, L., Butchar, J. P., Tridandapani, S., Croce, C. M., et al. (2012) · Blood · doi:10.1182/blood-2011-12-398099 · Cited by 203
Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells
Ahmed, N., Ratnayake, M., Savoldo, B., Perlaky, L., Dotti, G., Wels, W. S., Bhattacharjee, M. B., Gilbertson, R. J., Shine, H. D., Weiss, H. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4309 · Cited by 192
Clinical Cancer Therapy by NK Cells via Antibody‐Dependent Cell‐Mediated Cytotoxicity
Alderson, K. L., & Sondel, P. M. (2011) · BioMed Research International · doi:10.1155/2011/379123 · Cited by 156
Tamura, K., Shimizu, C., Hojo, T., Akashi-Tanaka, S., Kinoshita, T., Yonemori, K., Kouno, T., Katsumata, N., Ando, M., Aogi, K., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq585 · Cited by 186
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Nayyar, G., Chu, Y., & Cairo, M. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00051 · Cited by 177
Boullart, A. C. I., Aarntzen, E. H. J. G., Verdijk, P., Jacobs, J. F. M., Schuurhuis, D. H., Benítez‐Ribas, D., Schreibelt, G., van de Rakt, M. W. M. M., Scharenborg, N. M., de Boer, A. J., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0489-2 · Cited by 172
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Zhang, M., Wen, B., Antón, O. M., Yao, Z., Dubois, S. P., Ju, W., Sato, N., DiLillo, D. J., Bamford, R. N., Ravetch, J. V., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811615115 · Cited by 172
Clinical utility of natural killer cells in cancer therapy and transplantation
Knorr, D. A., Bachanova, V., Verneris, M. R., & Miller, J. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.002 · Cited by 170
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
Luchtel, R. A., Bhagat, T., Pradhan, K., Jacobs, W. R., Levine, M., Verma, A., & Shenoy, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908158117 · Cited by 167
Natural Killer Cells Produce T Cell–Recruiting Chemokines in Response to Antibody-Coated Tumor Cells
Roda, J. M., Parihar, R., Magro, C., Nuovo, G. J., Tridandapani, S., & Carson, W. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2429 · Cited by 165
Self-citationUtilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer
Romee, R., Leong, J. W., & Fehniger, T. A. (2014) · Scientifica · doi:10.1155/2014/205796 · Cited by 164
Roda, J. M., Joshi, T., Butchar, J. P., McAlees, J. W., Lehman, A., Tridandapani, S., & Carson, W. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0865 · Cited by 146
Self-citationCosta, R. L. B., & Czerniecki, B. J. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0153-3 · Cited by 158
Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
Qiu, Q., Lin, Y., Ma, Y., Li, X., Liang, J. B., Chen, Z., Liu, K., Huang, Y., Luo, H., Huang, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612202 · Cited by 152
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody
Awan, F. T., Lapalombella, R., Trotta, R., Butchar, J. P., Yu, B., Benson, D. M., Roda, J. M., Cheney, C., Mo, X., Lehman, A., et al. (2010) · Blood · doi:10.1182/blood-2009-06-229039 · Cited by 131
Juliá, E. P., Amante, A., Pampena, M. B., Mordoh, J., & Levy, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02140 · Cited by 139
Roda, J. M., Parihar, R., & Carson, W. E. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1619 · Cited by 132
Self-citationFOUTS, T. R., Bagley, K., Prado, I., Bobb, K., Schwartz, J. A. J., Xu, R., Zagursky, R. J., Egan, M. A., Eldridge, J. H., LaBranche, C. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423669112 · Cited by 130
Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets
Roda, J. M., Parihar, R., Lehman, A., Mani, A., Tridandapani, S., & Carson, W. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.120 · Cited by 119
Self-citationNanotechnology-enhanced immunotherapy for metastatic cancer
Zhang, P., Meng, J., Li, Y., Chen, Y., Hou, Y., Tang, W., McHugh, K. J., & Jing, L. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100174 · Cited by 123
Biology and clinical impact of human natural killer cells
Farag, S. S., VanDeusen, J. B., Fehniger, T. A., & Caligiuri, M. A. (2003) · International Journal of Hematology · doi:10.1007/bf02983234 · Cited by 121
Parihar, R., Nadella, P., Lewis, A., Jensen, R., De Hoff, C., Dierksheide, J. E., VanBuskirk, A. M., Magro, C. M., Young, D. C., Shapiro, C. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0265 · Cited by 111
Self-citationGut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
Combination Strategies to Enhance Antitumor ADCC
Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 111
Poh, A. R., & Ernst, M. (2021) · Cancers · doi:10.3390/cancers13122860 · Cited by 106
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
Repka, T. L., Chiorean, E. G., Gay, J., Herwig, K. E., Kohl, V., Yee, D., & Miller, J. S. (2003) · PubMed · Cited by 102
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production
Jaime-Ramirez, A. C., Mundy-Bosse, B. L., Kondadasula, S., Jones, N. B., Roda, J. M., Mani, A., Parihar, R., Karpa, V., Papenfuss, T. L., LaPerle, K. M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000328 · Cited by 100
Self-citationBill, M. A., Bakan, C. E., Benson, D. M., Fuchs, J. R., Young, G. S., & Lesinski, G. B. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0377 · Cited by 97
Lu, H., Yang, Y., Gad, E. A., Inatsuka, C., Wenner, C. A., Disis, M. L., & Standish, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1142 · Cited by 97
Muntasell, A., Cabo, M., Servitja, S., Tusquets, I., Martinez‐García, M., Rovira, A., Rojo, F., Albanell, J., & López‐Botet, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01544 · Cited by 97
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
Mandó, P., Rivero, S. G., Rizzo, M., Pinkasz, M., & Levy, E. M. (2021) · The Breast · doi:10.1016/j.breast.2021.08.007 · Cited by 90
Fischer, L., Penack, O., Gentilini, C., Nogai, A., Muessig, A., Thiel, E., & Uharek, L. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.02.015 · Cited by 87
Kondadasula, S. V., Roda, J. M., Parihar, R., Yu, J., Lehman, A., Caligiuri, M. A., Tridandapani, S., Burry, R. W., & Carson, W. E. (2008) · Blood · doi:10.1182/blood-2007-01-068908 · Cited by 76
Self-citationWidowati, W., Jasaputra, D. K., Sumitro, S. B., Widodo, M. A., Mozef, T., Rizal, R., Kusuma, H. S. W., Laksmıtawatı, D. R., Murti, H., Bachtiar, I., et al. (2020) · African Health Sciences · doi:10.4314/ahs.v20i2.36 · Cited by 83
Lesinski, G. B., Kondadasula, S. V., Crespin, T., Shen, L., Kendra, K., Walker, M., & Carson, W. E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh252 · Cited by 75
Self-citationCrosstalk between macrophages and natural killer cells in the tumor microenvironment
Zhou, J., Zhang, S., & Guo, C. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108374 · Cited by 81
Srivastava, S., Pelloso, D., Feng, H., Voiles, L., Lewis, D., Hašková, Z., Whitacre, M., Trulli, S. H., Chen, Y.-J., Toso, J. F., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1403-0 · Cited by 80
Ladoire, S., Arnould, L., Mignot, G., Apétoh, L., Rébé, C., Martin, F., Fumoleau, P., Coudert, B. P., & Ghiringhelli, F. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.261 · Cited by 77
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
Battella, S., Cox, M. C., Santoni, A., & Palmieri, G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr0415-141r · Cited by 77
Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function
Mace, T. A., Ware, M. B., King, S. A., Loftus, S. N., Farren, M. R., McMichael, E. L., Scoville, S. D., Geraghty, C. M., Young, G. S., Carson, W. E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41687-z · Cited by 76
Self-citationCytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives
Atallah‐Yunes, S. A., & Robertson, M. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872010 · Cited by 72
Luedke, E., Jaime-Ramirez, A. C., Bhave, N., Roda, J., Choudhary, M. M., Kumar, B., Teknos, T. N., & Carson, W. E. (2012) · Surgery · doi:10.1016/j.surg.2012.05.035 · Cited by 71
Self-citationBrown, A. C. N., Dobbie, I. M., Alakoskela, J.-M. I., Davis, I., & Davis, D. M. (2012) · Blood · doi:10.1182/blood-2012-05-429977 · Cited by 71
Natural Killer Cells - Their Role in Tumour Immunosurveillance
Sharma, P., Kumar, P., & Sharma, R. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/26748.10469 · Cited by 71
IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
McMichael, E. L., Jaime-Ramirez, A. C., Guenterberg, K. D., Luedke, E., Atwal, L. S., Campbell, A. R., Hu, Z., Tatum, A. S., Kondadasula, S. V., Mo, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0004 · Cited by 70
Self-citationMechanisms of Resistance to NK Cell Immunotherapy
Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 71
Role of microRNAs in COVID-19 with implications for therapeutics
Arghiani, N., Nissan, T. A., & Matin, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112247 · Cited by 69
Engineered natural killer cells for cancer therapy
Biederstädt, A., & Rezvani, K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.013 · Cited by 69
Le Page, A., Bourgade, K., Lamoureux, J., Frost, E., Pawelec, G., Larbi, A., Witkowski, J. M., Dupuis, G., & Fülöp, T. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143054 · Cited by 63
Wong, J. L., Mailliard, R. B., Moschos, S. J., Edington, H. D. J., Lotze, M. T., Kirkwood, J. M., & Kaliński, P. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31820b370b · Cited by 63
Positive and negative regulation of Natural Killer cells: Therapeutic implications
Hallett, W. H. D., & Murphy, W. J. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.003 · Cited by 63
Release of Biologically Functional Interferon-Alpha from a Nanochannel Delivery System
Lesinski, G. B., Sharma, S., Varker, K. A., Sinha, P. M., Mauro Ferrari, B., & Carson, W. E. (2005) · Biomedical Microdevices · doi:10.1007/s10544-005-6174-8 · Cited by 61
Self-citationImmune Therapy for Breast Cancer in 2010—Hype or Hope?
Florescu, A., Amir, E., Bouganim, N., & Clemons, M. J. (2011) · Current Oncology · doi:10.3747/co.v18i1.623 · Cited by 59
Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 58
Natural Killer Cells in Innate Immunity and Cancer
Becknell, B., & Caligiuri, M. A. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318182de23 · Cited by 56
Kinder, M., Greenplate, A. R., Strohl, W. R., Jordan, R. E., & Brezski, R. J. (2015) · mAbs · doi:10.1080/19420862.2015.1022692 · Cited by 55
Natural killer cells: the immune frontline against circulating tumor cells
Masmoudi, D., Villalba, M., & Alix‐Panabières, C. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03375-x · Cited by 53
Boero, S., Morabito, A., Banelli, B., Cardinali, B., Dozin, B., Lunardi, G., Piccioli, P., Lastraioli, S., Carosio, R., Salvi, S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0680-0 · Cited by 52
Park, Y.-K., Shin, D., Cho, D., Kim, S., Lee, J., Shin, M., Ryang, D., Lee, J. S., Park, M., Yoon, J. H., et al. (2012) · PubMed · Cited by 50
Suarez‐Kelly, L. P., Campbell, A. R., Rampersaud, I. V., Bumb, A., Wang, M. S., Butchar, J. P., Tridandapani, S., Yu, L., Rampersaud, A., & Carson, W. E. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.12.005 · Cited by 50
Self-citationMedina‐Echeverz, J., Hinterberger, M., Testori, M., Geiger, M., Giessel, R., Bathke, B., Kassub, R., Gräbnitz, F., Fiore, G., Wennier, S. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12998-6 · Cited by 49
Miah, S. M. S., Hughes, T. L., & Campbell, K. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2922 · Cited by 48
Mani, A., Roda, J. M., Young, D. C., Caligiuri, M. A., Fleming, G. F., Kaufman, P. A., Brufsky, A., Ottman, S., Carson, W. E., & Shapiro, C. L. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0251-7 · Cited by 48
Self-citationMcMichael, E. L., Benner, B. N., Atwal, L. S., Courtney, N. B., Mo, X. M., Davis, M. E., Campbell, A. R., Duggan, M. C., Williams, K., Martin, K. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2108 · Cited by 46
Self-citationRemotely Guided Immunobots Engaged in Anti‐Tumorigenic Phenotypes for Targeted Cancer Immunotherapy
Dogan, N. O., Ceylan, H., Suadiye, E., Sheehan, D., Aydın, A., Yasa, I. C., Wild, A., Richter, G., & Sitti, M. (2022) · Small · doi:10.1002/smll.202204016 · Cited by 44
Debbi, K., Grellier, N., Loganadane, G., Boukhobza, C., Mahé, M., Chérif, M., Rida, H., Gligorov, J., & Belkacémi, Y. (2023) · Cancers · doi:10.3390/cancers15082278 · Cited by 42
Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation
Suarez‐Kelly, L. P., Sun, S. H., Ren, C., Rampersaud, I. V., Albertson, D., Duggan, M. C., Noel, T. C., Courtney, N. B., Buteyn, N. J., Moritz, C., et al. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c00256 · Cited by 39
Self-citationBhatt, S., Parvin, S., Zhang, Y., Cho, H.-M., Kunkalla, K., Vega, F., Timmerman, J. M., Shin, S.-U., Rosenblatt, J. D., & Lossos, I. S. (2017) · Blood · doi:10.1182/blood-2016-09-738211 · Cited by 39
IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection
Kumar, P., Rajasekaran, K., Nanbakhsh, A., Gorski, J., Thakar, M. S., & Malarkannan, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41478-6 · Cited by 39
HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
Pupa, S. M., Tagliabue, E., Ménard, S., & Anichini, A. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20387 · Cited by 39
New directions in natural killer cell-based immunotherapy of human cancer
Farag, S. S., Fehniger, T. A., Becknell, B., Blaser, B. W., & Caligiuri, M. A. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.2.237 · Cited by 37
Trikha, P., Moseman, J. E., Thakkar, A., Campbell, A. R., Elmas, E., Foltz, J. A., Chakravarti, N., Fitch, J., Mardis, E. R., & Lee, D. A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004533 · Cited by 36
Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+T cells
Jung, K., Ha, J.-H., Kim, J., Kim, J.-A., Kim, Y., Kim, Y., & Kim, Y. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438800 · Cited by 35
Kaumaya, P. T. P., Guo, L., Overholser, J. P., Penichet, M. L., & Bekaii‐Saab, T. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1818437 · Cited by 35
Zimmerer, J. M., Lesinski, G. B., Ruppert, A. S., Radmacher, M. D., Noble, C., Kendra, K., Walker, M. J., & Carson, W. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0846 · Cited by 33
Self-citationViral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis
Chung, Y. H., Ortega-Rivera, O. A., Volckaert, B. A., Jung, E., Zhao, Z., & Steinmetz, N. F. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221859120 · Cited by 33
Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab: Potential for Immune Modulation
Luedke, E. A., Jaime‐Ramirez, A. C., Bhave, N. S., & Carson, W. E. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182562d76 · Cited by 33
Self-citationTLR9 and Glioma: Friends or Foes?
Fehri, E., Ennaifer, E., Rhouma, R. B. H., Ardhaoui, M., & Boubaker, S. (2022) · Cells · doi:10.3390/cells12010152 · Cited by 32
The Raf Kinase Inhibitor Sorafenib Inhibits JAK–STAT Signal Transduction in Human Immune Cells
del Campo, S. E. M., Levine, K. M., Mundy-Bosse, B. L., Grignol, V. P., Fairchild, E. T., Campbell, A. R., Trikha, P., Mace, T. A., Paul, B. K., Jaime‐Ramirez, A. C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400084 · Cited by 32
Self-citationBertino, E. M., McMichael, E. L., Mo, X. M., Trikha, P., Davis, M. E., Paul, B. K., Grever, M. R., Carson, W. E., & Otterson, G. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0879 · Cited by 33
Self-citationStewart, C. M., Phan, A., Bo, Y., LeBlond, N. D., Smith, T. K. T., Laroche, G., Giguère, P. M., Fullerton, M. D., Pelchat, M., Kobasa, D., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009275 · Cited by 32
Marquez, M., Millet, C., Stekman, H., Conesa, A., Deglesne, P., Toro, F., Sanctis, J. B. D., & Blanca, I. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.05.002 · Cited by 31
Ramamoorthi, G., Kodumudi, K. N., Snyder, C., Grover, P., Zhang, H., Greene, M. I., Basu, A. B., Gallen, C., Wiener, D. A., Costa, R. L. B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004841 · Cited by 30
Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15.
Sheikhi, A., Jafarzadeh, A., Kokhaei, P., & Hojjat‐Farsangi, M. (2016) · PubMed · doi:10.22034/iji.2016.33404 · Cited by 30
Direct and Indirect Effect of TNFα and IFNγ Toward Apoptosis in Breast Cancer Cells
Widowati, W., Jasaputra, D. K., Sumitro, S. B., Widodo, M. A., Afifah, E., Rizal, R., Rihibiha, D. D., Kusuma, H. S. W., Murti, H., Bachtiar, I., et al. (2018) · Molecular and Cellular Biomedical Sciences · doi:10.21705/mcbs.v2i2.21 · Cited by 30
Faneca, H., Cabrita, A., Simões, S., & de Lima, M. C. P. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.12.017 · Cited by 30
Metadata
- Authors
- Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University (US)
- Corresponding author
- Carson, William E.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-10-01
- Volume
- 110
- Issue
- 7
- Pages
- 983-992
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4237052860
- Cited by
- 23
- References
- 40
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2015: 2 · 2014: 1 · 2013: 1
- FWCI
- 0.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Funders
- Ohio State University
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- IL-12, natural killer cells, monoclonal antibodies, antitumor immunity, FcγRIII, IL-12 receptor, monocytes, antibody-dependent cellular cytotoxicity, anti-idiotypic antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.